Allergan's Lap-Band AP approved in Europe for diabetes
This article was originally published in The Gray Sheet
Adjustable gastric banding system for obesity intervention becomes the first such device to gain European market approval for weight loss that leads to improvement or remission of type 2 diabetes, the firm announces June 26. The approval was supported by results of a two-year randomized trial that confirmed results from previous observational studies. The study showed that patients who lost weight with Lap-Band AP were over five-times more likely to achieve remission of type 2 diabetes than patients receiving conventional diabetes therapy (73% vs. 13%). Expanded labeling for the device states that weight loss associated with the system "has been shown to improve or lead to remission of type 2 diabetes," the company says
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.